"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Several FDA-approved drugs exist for treating alcohol use disorder (AUD), but they are seldom prescribed in general practice.

Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Glucose Tablets 3-4 tablets Provides precise dose, often convenient to carry. Glucose Gel 1 tube Fast-acting and easy to swallow. If available, administer a glucagon injection immediately. Glucagon is ...

Irvine-based medical device company Beta Bionics Inc. on Jan. 6 filed an S-1 with the Securities and Exchange Commission to list on the Nasdaq under the symbol “BBNX.” ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, ...